It has been 50 years since Dr. William B. Kannel coined the term “factors of risk” in relation to cardiovascular disease (1). Since then, clinical risk assessment, including the use of circulating biomarkers, has become an integral part of medical practice. The current era of genomics, proteomics, and metabolomics is projected to lead to the discovery of an immense number of novel candidate bio...